首页> 外文期刊>Gene therapy >Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA.
【24h】

Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA.

机译:长期抑制双链腺相关病毒8传递的短发夹RNA的转基因小鼠乙型肝炎病毒。

获取原文
获取原文并翻译 | 示例
           

摘要

RNA interference (RNAi) was reported to block hepatitis B virus (HBV) gene expression and replication in vitro and in vivo. However, it remains a technical challenge for RNAi-based therapy to achieve long-term and complete inhibition effects in chronic HBV infection, which presumably requires more extensive and uniform transduction of the whole infected hepatocytes. To increase the in vivo transfection efficiency in liver, we used a double-stranded adeno-associated virus 8-pseudotyped vector (dsAAV2/8) to deliver shRNA. HBV transgenic mice were used as an animal model to evaluate the inhibition effects of the RNAi-based gene therapy. A single administration of dsAAV2/8 vector, carrying HBV-specific shRNA, effectively suppressed the steady level of HBV protein, mRNA and replicative DNA in liver of HBV transgenic mice, leading to up to 2-3 log(10) decrease in HBV load in the circulation. Significant HBV suppression sustained for at least 120 days after vector administration. The therapeutic effect of shRNA was target sequence dependent and did not involve activation of interferon. These results underscore the potential for developing RNAi-based therapy by dsAAV2/8 vector to treat HBV chronic infection, and possibly other persistent liver infections as well.
机译:据报道,RNA干扰(RNAi)可以在体内外阻断乙型肝炎病毒(HBV)基因的表达和复制。然而,对于基于RNAi的治疗在慢性HBV感染中实现长期和完全抑制作用仍然是一项技术挑战,这可能需要对整个被感染的肝细胞进行更广泛,更统一的转导。为了增加在肝脏中的体内转染效率,我们使用了双链腺相关病毒8-假型载体(dsAAV2 / 8)来递送shRNA。 HBV转基因小鼠被用作动物模型,以评估基于RNAi的基因疗法的抑制作用。携带HBV特异性shRNA的dsAAV2 / 8载体的单次给药有效抑制了HBV转基因小鼠肝脏中HBV蛋白,mRNA和复制性DNA的稳定水平,从而导致HBV载量最多降低2-3 log(10)在流通中。给予载体后,HBV的显着抑制作用持续至少120天。 shRNA的治疗作用是靶序列依赖性的,不涉及干扰素的激活。这些结果强调了通过dsAAV2 / 8载体开发基于RNAi的疗法以治疗HBV慢性感染以及可能的其他持续性肝感染的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号